Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $7.73B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: ALKS stock price vs PCG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PCG's multiple
Needs PCG P/E.
Implied fair value · at ALKS's multiple
Needs ALKS P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALKS FY 2025 (ended Dec 31, 2025) · PCG FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 5.19x · EV / EBITDA 23.76x
Capital structure 40% equity / 60% debt · EV / Revenue 3.84x · EV / EBITDA 18.83x
PCG carries the larger enterprise value at $95.82B against $7.66B; PCG trades on the lower EV / Revenue multiple (3.84x vs 5.19x); PCG on the lower EV / EBITDA (18.83x vs 23.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Alkermes plc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
PG&E CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.17x
1.79x
Net debt / EBITDA
Leverage against operating earnings
-0.22x
11.30x
Cash and equivalents
Liquid reserves on the balance sheet
$388.57M
$713.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
ALKS vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
ALKS vs SUPN
Amneal Pharmaceuticals, Inc.
ALKS vs AMRX
SEMPRA
ALKS vs SRE
Duke Energy CORP
ALKS vs DUK
COMCAST CORP
ALKS vs CMCSA
DTE ENERGY CO
ALKS vs DTE
PUBLIC SERVICE ENTERPRISE GROUP INC
ALKS vs PEG
NATIONAL FUEL GAS CO
ALKS vs NFG
$317.13M
$58.21B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
